The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Sequencing anti-CD38 antibodies in multiple myeloma
Albert Oriol, MD, PhD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, discusses how prior anti-CD38 antibody exposure should be considered when sequencing treatment for patients with multiple myeloma. He highlights the potential value of using alternative drug targets where available, while noting that re-exposure to an anti-CD38 antibody may remain an option when alternatives are limited, particularly after a longer treatment-free interval. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
